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Abstract 
Interventional endoscopy of the upper gastrointestinal tract is a rapidly evolving surgical discipline 
that minimizes the surgical trauma. Yet, complications occur that sometimes are severe. This thesis 
aims to improve upper gastrointestinal endoscopic therapeutic procedures by addressing aspects of 
their complications in three randomised clinical trials (paper I-III) and one prospective cohort study 
(paper IV). 
In distal oesophageal tumours the palliative placement of stent, against dysphagia, crosses the 
gastrooesophageal junction, thus possibly causing reflux-induced severe oesophagitis and aspiration. 
Therefore, in paper I, a multicentre trial was performed with the intention of improving the health-
related quality of life (HRQL) by testing an anti-reflux stent after palliative stenting of patients with 
inoperable distal oesophageal cancer. The 65 patients included were randomised for an anti-reflux 
stent or a conventional stent. HRQL was measured using validated questionnaires assessing general 
and oesophageal-specific symptoms and functions (EORTC QLQ-C30 and QLQ-OES18) at baseline, 
and both one and three months after stenting. No statistically significant differences were found 
between the two types of stents. 
Some research has indicated that the antihypertensive angiotensin II receptor blocker (ARB) losartan 
might prevent acute pancreatitis. Therefore, in paper II, we conducted a placebo controlled trial that 
tested whether losartan prevents hyperenzymemia (a marker of acute pancreatitis) as assessed 24 hours 
after endoscopic retrograde cholangiopancreatography (ERCP). Among 76 randomised patients, there 
was no evidence of any preventive effect of losartan on such hyperenzymemia. 
A significant problem after insertion of nutritional percutaneous endoscopic gastrostomy (PEG) is 
peristomal infection. A standard antibiotic prophylaxis of 1.5 g cefuroxime (Zinacef
®
) given 
intravenously one hour before PEG insertion is generally recommended. In paper III, to develop and 
facilitate such prophylaxis, we tested whether antibiotic prophylaxis with 20 ml oral solution 
sulphamethoxazole/trimethoprim (Bactrim
®
) given in the newly inserted PEG catheter could replace 
the standard treatment. Among 234 randomised patients, 10 and 14 peristomal infections occurred in 
the sulphamethoxazole/trimethoprim and the cefuroxime group, respectively. The intention-to-treat 
and per-protocol analyses both revealed that the sulphamethoxazole/trimethoprim strategy was at least 
as effective as standard antibiotic prophylaxis. 
The risk factors for peristomal infections and early mortality after PEG insertion are uncertain. In 
paper IV we therefore conducted a hospital-based prospective cohort study addressing six potential 
risk factors for infectious complications or 30-day mortality after PEG insertion: age ≥ 65 years, BMI 
<18.5 kg/m
2
, albumin <30 g/L, C-reactive protein (CRP) ≥10 mg/L, indications for PEG, and co-
morbidities. After adjustment for potential confounders: advanced age, low albumin and high CRP 
levels were followed by a statistically significantly increased risk of short-term mortality. Compared to 
the 2.6% risk of mortality in patients with normal albumin and CRP levels, a combination of low 
albumin and high CRP rendered a greater than 7-fold increased risk (OR, 7.45; 95% confidence 
interval, 2.62-21.19) or a mortality rate of 20.5%.  
In summary, antireflux stents might not be superior to conventional stents in the palliation of 
dysphagia in patients with distal oesophageal cancer. Losartan does not seem to reduce 
hyperenzymemia after ERCP. A local solution of 20 ml sulphamethoxazole/trimethoprim can probably 
replace standard antibiotic prophylaxis during PEG insertion. Low albumin and high CRP are markers 
of increased risk of early mortality after PEG insertion. 
 
 
6 
List of original publications 
 
This thesis is based on the following papers, which will be referred to in the text by 
their Roman numerals (I-IV). 
I John Blomberg, Urs Wenger, Jesper Lagergren, Urban Arnelo, Torhallur 
 Agustsson, Erik Johnsson, Ervin Toth, Pernilla Lagergren. 
 Anti-reflux stent versus conventional stent in the palliation of distal 
 esophageal cancer. A randomised, multicenter clinical trial.  
 Scandinavian Journal of Gastroenterology 2010;45(2):208-16 
II Tomas Sjöberg Bexelius, John Blomberg, Yunxia Lu, Hans-Olof 
 Håkansson,  Peter Möller, Carl-Eric Nordgren, Urban Arnelo, Jesper 
 Lagergren, Mats Lindblad. 
 Angiotensin II receptor blocker losartan and the prevention of 
 hyperenzymemia after endoscopic retrograde 
 cholangiopancreatography: a randomised clinical trial.  
 Submitted manuscript. 
III John Blomberg, Pernilla Lagergren, Lena Martin, Fredrik Mattsson, 
 Jesper Lagergren. 
 Novel approach to antibiotic prophylaxis in percutaneous endoscopic 
 gastrostomy (PEG): randomised controlled trial. 
 British Medical Journal 2010 Jul 2;341:c3115.   
IV John Blomberg, Pernilla Lagergren, Lena Martin, Fredrik Mattsson, 
 Jesper Lagergren. 
 Albumin and C-reactive protein levels predict short-term mortality 
 after percutaneous endoscopic gastrostomy (PEG) in a prospective cohort 
 study. 
 Gastrointestinal Endoscopy (In press),   
 
 
 
 
The published papers were reprinted with the kind permission of TAYLOR & 
FRANCIS A S (paper I), BMJ Publishing Group Ltd (paper III) and Elsevier (paper 
IV).  
7 
An overview of the studies 
 Question Patients and 
methods 
Results Conclusion 
I Are anti-reflux stents 
better than conventional 
stent regarding health 
related quality of life 
(HRQL) in palliative 
treatment of dysphagia 
in patients with 
inoperable distal 
esophageal cancer? 
Double-blinded 
randomised multicentre 
trial between 2003-2007 
including 72 patients. 
HRQL questionnaires 
QLQ-C30 and QLQ-
OES18 were registered at 
baseline and at 1 and 3 
months. 
No differences in 
HRQL scores were 
found between the 
comparison groups. 
No benefit in 
using anti-reflux 
stent compared to 
conventional 
stent.  
II Does 50mg losartan 
given 1 hour before 
endoscopic retrograde 
cholangiopancreatogr-
aphy (ERCP) reduce 
hyperenzymemia after 
ERCP? 
Triple-blinded randomised 
placebo-controlled clinical 
trial between 2006-2008 
including 76 patients. 
Serum levels of amylase 
and lipase 24 hour after 
ERCP were evaluated. 
No reductions in 
amylase or lipase 
levels after ERCP 
were found.  
No support for the 
hypothesis that 
50mg losartan 
prevents 
hyperenzymemia 
after ERCP.  
III Is 20 ml 
sulphamethoxazole/trim
ethoprim in the catheter 
after percutaneous 
endoscopic 
gastrostomy (PEG) at 
least as effective as 
standard antibiotic 
prophylaxis in the 
prevention of peristomal 
infection? 
Double-blind randomised 
clinical trial between 
2005-2009, including 234 
patients. Standard 
treatment was 1.5 g 
cefuroxime given 1 hour 
before PEG. Peristomal 
infection was assessed at 
follow-up within 14 days 
after PEG insertion. 
No difference was 
found in infection 
frequency between the 
comparison groups. 
Sulphamethoxazo
le/trimethoprim is 
at least as 
effective as 
standard 
treatment for 
antibiotic 
prophylaxis in 
PEG insertion. 
IV Which are the risk 
factors for short-term 
mortality and peristomal 
infection after PEG? 
A prospective cohort 
study evaluating 484 
patients receiving a PEG 
catheter between 2005-
2009 at Karolinska 
University Hospital in 
Solna. The study 
assessed pre-determined 
potential risk factors: age, 
body mass index (BMI), 
albumin, C-reactive 
protein (CRP), indication 
for PEG and co-morbidity. 
Patients aged ≥65, 
with albumin <30g/L 
and CRP ≥10mg/L had 
an increased risk of 
mortality and possibly 
of peristomal infection. 
The combination of 
low albumin and high 
CRP resulted in a 7-
fold increased risk of 
mortality, and an 
absolute mortality risk 
of 20.5% compared to 
2.6 %, when both 
these values were 
normal. 
Albumin and CRP 
levels predict 
short-term 
mortality after 
PEG. 
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Introduction 
Endoscopy (endo- prefix referring to something internal, and scopy, to see; both words 
are of Greek origin) originally means to look inside something. Today endoscopy 
mainly represents the use of flexible or rigid instruments to look inside body cavities. 
“Interventional endoscopy” implies that the endoscopy includes some kind of surgical 
treatment. The instrument used for interventions in this thesis is flexible but of 
different designs. The development of new instruments and the gathering of new 
endoscopic skills allow more advanced endoscopic surgical procedures. An increasing 
palette of complications is therefore to be expected but, compared to the alternative 
surgical procedures, the number and severity of complications is probably less and, as 
an extra enticement, the endoscopic procedures leave no visible scars, except when 
specific complications occur. Identification of the different complications, of how 
often they occur, of risk factors for developing complications and, most importantly, 
of ways of avoiding them or making them less severe is of utmost clinical importance. 
My interest in endoscopic procedures and clinical knowledge of diagnostic and 
therapeutic endoscopy has given me insight into the consequences of complications. 
These complications could decrease patients' quality of life, lengthen their hospital 
stay, add costs and sometimes cause early mortality. This knowledge has stimulated 
my interest in finding measures to reduce complications and suffering caused by 
interventional endoscopy in the upper gastrointestinal tract, and in trying to make the 
procedures more efficient. There are many interventional procedures with different 
sets of complications, but I have focused in this thesis on a few common endoscopic 
interventions: 1/ Insertion of self-expanding metal stents (SEMS) for palliation of 
inoperable malignant oesophageal cancer, 2/ Endoscopic retrograde 
cholangiopancreatography (ERCP) used to investigate and treat problems in the bile 
duct or the pancreatic duct, and 3/ Insertion of percutaneous endoscopic gastrostomy 
(PEG) catheter, performed mainly for nutritional reasons. 
The present thesis evaluates: 1/ The role of anti-reflux stents in the palliative stenting 
of inoperable distal oesophageal cancer regarding health-related quality of life 
(HRQL), 2/ The prophylactic effect of losartan on hyperenzymemia after ERCP, 3/ A 
new method of antibiotic prophylaxis against peristomal infection after PEG insertion, 
and 4/ Potential risk factors for short-term mortality and peristomal infections after 
PEG. 
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Background 
Historical development of upper gastrointestinal endoscopy 
Hippocrates (460-ca 375 BC) wrote the first known description of an investigation into 
the anal canal and rectum, with a device using an ambient light source, a rectal 
speculum, in his treaty on fistula.
1
 The problem in early attempts to perform 
endoscopy was to direct strong enough light into the tubes. The Arabian physician 
Albukasim (936-1013 AD) is said to be the first to have used reflected light to inspect 
the cervix.
2
 It was not until Bozzini (1773-1808) in 1806 developed an instrument 
(“Lichtleiter”) with mirrors and a wax candle light source that a better view could be 
achieved. It allowed inspection of the urethra, urinary bladder, rectum, mouth and even 
vocal cords.
1, 2
 Development continued slowly with different lens systems for 
condensing light. For instance, Désormeaux demonstrated in 1853 the open tube 
endoscope with a burner, fuelled by a mixture of alcohol and turpentine, for 
illumination, allowing inspection of the urethra and urinary bladder.
2
  These methods 
were not well accepted by the medical profession of the time, who looked upon the 
invention as a mere toy. The first to develop a distal light with a glowing platinum 
wire with water cooling was the dentist Julius Bruck,
1
 but his strategy did not offer any 
possibilities for looking deeper inside the body and there was a risk of thermal injury 
involved.  
Probably the first documented inspection into the “live” stomach of a human was 
reported by Dr William Beaumont in 1853. He saw a patient with an abdominal 
gunshot wound that subsequently developed into a 5 cm wide gastro-cutaneous fistula, 
which facilitated inspection of the gastric mucosa and the study of gastric physiology.
3, 
4
 There were not many patients with such fistulas so, in 1868, Dr Adolf Kussmaul, 
inspired by a sword swallower, used the Désormeaux rigid endoscope to look down 
into the oesophagus and the stomach, but the light was not good enough. He described 
the situation by saying “we looked in vain into the darkness”.5 
Nitze, a general practitioner mainly interested in the urinary bladder, worked with 
instrument makers and opticians to develop the first cystoscope in 1877. He used a 
platinum wire protected by glass at the distal end of the scope and, after Edison’s 
invention of the filament globe in 1879, they managed to fit a miniaturised version of 
this to fit at the end of the cystoscope.
1
 The next step was taken by Professor Johann 
von Mikulicz-Radecki in Kraków 1881. He constructed and tested a modified Nitze 
cystoscope, which was 650 mm long, had a diameter of 13 mm, a 130
o
 angled tip fitted 
with a globe for illumination and an airway channel for insufflation, and this was used 
to look into the oesophagus and stomach.
1, 6
 This method of gastric inspection must 
have been very unpleasant for the patient, however. It was not until 1932 that the 
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German Dr Rudolf Schindler together with an instrument-maker and technician, Georg 
Wolf, improved gastroscopy sufficiently to make it less troublesome to patients and 
physicians. They constructed a semi-flexible, side-viewing gastroscope equipped with 
48 lenses and electric light at its tip.
7
 So far it was only possible to have a look at the 
mucosal surface, with no possibility to intervene other than perhaps to push down 
things that had got stuck in the oesophagus. To be able to do more there was a need for 
additional manoeuvrability, better optics and light, and separate working channels for 
interventional instruments.  
In 1956, Dr Basil Hirschowitz, a South African gastroenterologist, developed the fully 
flexible endoscope with glass fibre optics, and this development could be labelled the 
beginning of modern endoscopy.
8, 9
 Later, working channels used for interventional 
endoscopic instruments were added.
10
 The videoscope, developed in 1984, made 
documentation easier and resolution was improved with the introduction of a Charge-
Coupled Device (CCD) or electronic light sensor at the endoscopic tip.
11
 These 
technical developments have made video documentation and more advanced 
interventions of the gastrointestinal tract possible.  
There are now a number of therapeutic possibilities, e.g. treatment of oesophageal 
varices, dilatation of achalasia, stenting of gastrointestinal strictures and ruptures, 
stopping ulcer bleeding, excision of polyps or other mucosal lesions, drainage of peri-
duodenal or peri-gastric abscesses, percutaneous endoscopic gastrostomy (PEG), and 
interventions in the pancreatic and biliary ducts with the help of ERCP. At the 
beginning of the 21st century, an interesting novel technique began to develop: natural 
orifice transluminal endoscopic surgery (NOTES), which is supposed to allow surgery 
inside the abdomen or thorax by entering these cavities with flexible endoscopes 
through the walls of the oesophagus, stomach, colon, urinary bladder or the vagina. 
However, many problems remain to be solved with this technique before possibly 
introducing it as an alternative to laparoscopic and thoracoscopic surgery. The problem 
with all these more advanced endoscopic procedures is that their introduction is 
followed by an increased occurrence of complications that could sometimes be 
devastating.
12-15
 Knowledge of these complications, how to deal with them and how 
they are prevented, has improved, but there is still much to be learned. 
 
Modern endoscopes 
Fully flexible video gastroscopes used for interventions in the adult oesophagus, 
stomach and duodenum, usually have a diameter of about 8-13 mm, a 0
o
 frontal 
viewing CCD, one or more working channels of varying dimensions, a flushing and 
airflow channel, suction capabilities, and light, inside a metal coil of wire which is 
wrapped in a smooth rubberlike material (see the figure of a gastroscope on the front 
page). The endoscope could be made stiffer by rotating the metal coil in the endoscope 
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casings, which is used in some situations when managing sharp bends as in the first 
part of the duodenum. This is the current scope of choice when conducting PEG 
insertion and oesophageal stenting. Movements at the endoscopic tip are operated 
manually with two manually guided turning wheels connected to wires which bend the 
tip of the scope in four different directions. The movements can be augmented by 
twisting the instrument, allowing movements in nearly all directions, only limited by 
the luminal diameter of the bowel. The video image is viewed on a high resolution 
screen in front of the endoscopist. Programmable buttons on the scope could be used 
for a variety of functions, e.g. image freezing and saving. 
A video duodenoscope is used for diagnostic and interventional procedures in the 
duodenum, and the bile or the pancreatic ducts. The scope, used for adults, usually has 
a diameter of 11-13 mm, and 90
o
 side viewing, making manoeuvring more difficult to 
learn as compared to gastroscopy. Moreover, a movable elevator near the end of the 
endoscope is used to angulate different instruments put down through the working 
channel, facilitating the intubation of the bile 
or the pancreatic duct, see Figure 1.  
 
Figure 1. The tip of a duodenoscope with a 
guide wire inserted through a balloon catheter 
which is angled by the elevator.  
Artwork is reproduced, with permission, from the 
Johns Hopkins Gastroenterology and Hepatology 
Resource Center, www.hopkins-gi.org, copyright 
2010, Johns Hopkins University, all rights reserved. 
 
 
It is also possible to put down a thin manoeuvrable endoscope through the working 
channel of the duodenoscope, to inspect the bile and pancreatic ducts for visualisation 
of pathologic changes, directed tissue sampling, and pulverizing big stones with laser 
probes or electro-hydraulic stone crushers (lithotripter). The duodenoscope is also 
equipped with water flushing, air or carbon dioxide (CO2, which disappears more 
quickly than air) flow, and suction and light capabilities. Movements at the distal end 
of the endoscope are otherwise regulated as in the gastroscope above. 
 
Self-expandable oesophageal metallic stents  
The word stent probably originates from the English dentist Charles Stent (1807-1885) 
who developed a compound which he used to make accurate impressions of the oral 
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cavity to make better dentures. During the first world war a Dutch plastic surgeon Dr 
J.F. Esser used the “Stent compound” to reconstruct war wounds of the face, using the 
material as a “stent mold” for skin grafts.16 Later the noun stent became a word for 
“custom-built steel or hard plastic tubes inserted into strictured vessels or the 
gastrointestinal tract. 
The use of an oesophageal stent was first described in 1845 by Dr. Leroy d´Étoilles 
using an ivory tube inserted because of an oesophageal stricture.
17
 Early methods of 
stent fixation used threads from the stent knotted to the moustache, or threads taken 
out through the nostrils and tied around the neck.
17
 Stiff plastic tubes were introduced 
during the 1950s, and one of the first descriptions came in 1983, by Frimberger, of a 
spiral metallic stent put in place over the scope for palliation in ten patients with 
inoperable oesophageal cancer.
18
 After Domschke et al reported the use of a self-
expandable mesh stent in 1990,
19
 the development of  self-expandable metallic stents 
(SEMS) in the oesophagus gained momentum. The dominating symptom in 
oesophageal cancer is dysphagia, and stent insertion has become the most frequent 
palliative procedure in inoperable patients, due to the technically easy insertion and the 
rapid effect of decreasing dysphagia.
20
 SEMS can sometimes also be used for benign 
oesophageal strictures,
21
 spontaneous or post-surgery oesophageal ruptures,
22
 bleeding 
oesophageal varices,
23
 fistulae to the airway.
24
 The effect of endoscopic dilations on 
oesophageal cancer strictures is often of a very short duration, and as incurable 
patients with oesophageal cancer have a short life expectancy the primary use of 
SEMS is often the procedure of choice.
25
 If the cancer patient is expected to live 
longer than 3 months, however, brachytherapy (internal radiation therapy) can be 
contemplated as an alternative to stents because of the reported better HRQL beyond 3 
months compared to stents.
26 
Today, there are in principle three different open metallic stent designs available. The 
stain-less steel zig-zag wire stent, the stain-less steel mesh stent, and the nitinol 
(nickel-titanium alloy) mesh stent. No randomised study has yet shown any significant 
differences of effect in stent design on relief of dysphagia or complications.
27, 28
 As 
uncoated stents have a disturbing incidence of tumour ingrowth of 20-30%, a plastic 
coating of polyurethane or silicone has been added to reduce this effect.
29
 A higher risk 
of stent migration might follow the use of coated stents compared to uncoated stents, 
especially in the region of the distal oesophagus and gastric cardia (gastrooesophageal 
junction). A randomised study of 62 patients with obstructing tumours at the 
gastrooesophageal junction showed no significant difference in migration rate between 
covered and uncovered Ultraflex
®
 stents, however, while others have found a slightly 
elevated risk of migration when covered stents extend beyond the oesophagogastric 
junction.
30, 31
 Covered stents of larger diameter seem to have a decreased risk of 
migration and also better patency, but maybe to the price of more complications, as 
compared to stents of smaller diameter,.
27, 32
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Stents that pass the oesophagogastric junction, thus impairing the reflux-preventing 
mechanism, may possibly increase the risk of reflux-induced esophagitis and 
aspiration which could cause pneumonitis or pneumonia.
29
 This could be an 
increasingly common problem for several reasons: the incidence of adenocarcinoma of 
the oesophagus is increasing fast and most of these tumours are located near the 
gastrooesophageal junction,
33
 the majority of patients are inoperable, and nearly all 
develop progressive dysphagia.
34
 Therefore, stents with an antireflux mechanism have 
been designed with the aim of counteracting reflux (see Figure 4, page 34). However, 
they have, not so far proved their efficacy in preventing these problems and are more 
complicated to insert than conventional SEMS.
35-38
 Many endoscopists advocate the 
use of proton pump inhibitors (PPI) in patients receiving distal conventional stents to 
reduce the amount of refluxing acid from the stomach, although the effect on 
symptoms seems doubtful.
39
 
Plastic stents (SEPS) with total silicone covering (Polyflex
®
 Boston Scientific, 
Helsingborg, Sweden) or biodegradable stents (BD ELLA®, Ella-CS, Hradec Králové, 
Czech Republic) have been introduced mainly for the treatment of benign strictures, 
where multiple dilation has been unsuccessful, but SEPS are complicated to assemble 
and insert, and have a high migration rate.
40
  
 
PEG catheters 
Modern gastrostomy catheters are usually made of silicone (see Figure 2), a soft 
pliable material, or polyurethane which is stiffer but can have thinner tube walls and 
thus, a slimmer design. The polyurethane catheters also seem to have better patency 
than silicone-based catheters.
41
 
 
 
Figure 2. A Mic-PEG
®
.  The silicone PEG 
catheter with its inner flange and the not yet 
fitted outer stopper for maintaining the position 
of the PEG. The stopper is slipped on the catheter 
after which the white plastic cone with the loop 
thread is cut away. Then the adapter is positioned 
on the catheter end. 
Reproduced by kind permission of MEDA AB, Solna, 
Stockholm, Sweden. 
 
 
 
 
Latex catheters should be avoided because of short term durability and allergic 
reactions.
42
  The PEG catheter flange in the stomach stops the catheter from slipping 
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out. It can be hard or soft, which is important to know as this determines which 
method to use when removing the PEG. If the stopper is soft it is easy to extract, 
however, if it consists of hard plastic, it perhaps should be taken out through the mouth 
by gastroscopy after cutting the catheter close to the skin level (“cut and push” 
technique), especially if  there is a known history of bowel disease. Otherwise, if just 
dropped into the gastrointestinal tract, it has been reported to cause obstruction.
43
 This 
flange can also be a fixed or a refillable balloon, usually easy to extract after deflation 
when catheter exchange is required, with no need for gastroscopy. Commonly used 
silicone PEGs in adult patients in Sweden have a diameter of 20 Fr (or Charrière). 
Smaller diameter catheters seem prone to a higher dysfunction frequency than large-
bore catheters. 
 
Health Related Quality of Life (HRQL) 
When evaluating outcomes of different treatment options in non-curable cancer 
patients, HRQL plays the key role. When assessing HRQL it is important to show how 
it is defined, since there are many different definitions and variations in the literature 
with the WHO´s declaration of health from 1948 seeming to be one of the broadest: “a 
state of complete physical, mental and social wellbeing, and not merely the absence of 
disease”. Quality of life means different things to different people depending on the 
area of usage and is often supposed to be intuitively understood.
44
 From a clinical trial 
perspective the WHO definition seems too broad because the main interest is usually 
“aspects affected by disease and treatment for disease”.44 The definition of quality of 
life used in paper I has more limited scope, and is stated as being: multifactorial and 
including functional status, psychological and social well-being, the self-perception of 
general health as well as disease and treatment specific symptoms.
45
 The instruments 
chosen, to assess HRQL in paper I, were developed by the European Organisation of 
Research and Treatment of Cancer, EORTC, founded in 1962, as an international non-
profit organisation. The general cancer core questionnaire, QLQ-C30 version 3, 
comprises 30 questions, containing scales and items addressing five functional 
dimensions (physical, daily activity or role, cognitive, emotional and social function) 
of HRQL and three symptom scales (fatigue, pain and nausea/vomiting) as well as five 
single items (shortness of breath, loss of appetite, sleeping difficulties, constipation 
and diarrhoea) that commonly occur in patients with cancer. Moreover, the QLQ-C30 
includes one question assessing the financial impact of malignant disease, and one 
global HRQL scale. To improve the sensitivity and specificity of disease-specific 
issues,
46
 a module, QLQ-OES18, with 18 questions addressing symptoms common in 
patients with oesophageal cancer can be added. This questionnaire includes four 
symptom scales (dysphagia, eating difficulties, reflux and oesophageal pain) and six 
single items (trouble swallowing saliva, choking, dry mouth, taste problems, cough, 
and speech difficulties). These questionnaires are self-administered and easy to fill in 
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(it takes about 10-15 minutes) and can be completed at home without the surrounding 
influence of health or study personnel. The QLQ-C30 together with the QLQ-OES18 
module used in paper I are well validated (measures what they are intended to 
measure) and show acceptable reliability (degree of random variability and 
reproducible results) and are recommended for use when evaluating different treatment 
options in oesophageal cancer patients regarding HRQL.
47
 Since the questionnaires 
have been translated into several languages and have been used all over Europe for 
more than two decades, the results could be compared with other trials assessing 
HRQL in palliative oesophageal cancer patients. 
The raw scores of the scales and items are usually linearly transformed, according to 
the recommendations of the EORTC manual, to a scale of 0-100 points.
48
 In large 
studies there could be a statistically significant difference between measures of only a 
couple of points, which is meaningless from a clinical point of view, since such 
differences are not noted by the patient. Therefore, the term “clinically relevant 
difference” has been introduced. This represents a difference that the patient can 
realise as a moderate change at least and it is commonly set at ≥ 10 points.46, 49 A 
common approach is to perform formal statistical tests only where clinically relevant 
differences are identified to avoid multiple testing and chance findings. 
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Endoscopic interventions addressed in this 
thesis 
 
Therapeutic endoscopy is usually performed after 6 hours of fasting. Local anaesthesia 
(1% lidocain) is sprayed on the throat mucosa after which intravenous sedation with 
midazolam (a benzodiazepine) or sometimes full anaesthesia with intubation and 
regulated respiration is used before the endoscope is introduced. Intravenous opiates 
are used for analgesia as required. At some centers deep sedation by using bolus 
injections of propofol, normally used for induction of general anaesthesia, is preferred, 
but under the responsibility of anaesthesiologists. 
 
Oesophageal stenting 
The stent procedure is typically done with a 0
o
 front-viewing gastroscope often with 
the help of fluoroscopy to facilitate exact positioning of the stent. If the malignant 
stricture is too tight, dilation may enable the stricture to pass but could introduce a risk 
of tumour rupture. A guide wire is put down through the working channel of the 
endoscope and the distal end is left in place beyond the stricture, preferably down into 
the duodenum, to reduce the risk of gastric perforation by the stent delivery system 
during insertion. The endoscope is retracted leaving the guide wire in place. The stent, 
compressed in its delivery coating, is introduced over the guide wire usually under 
fluoroscopic control. After deployment, the expansion of the stent and its position is 
often checked by looking down again with the endoscope. It usually takes 48 or 72 
hours for full stent expansion and the dysphagia almost always improves.
29
 
 
ERCP 
ERCP was first mentioned in 1965 by Rabinov in Boston
50
 in a preliminary report of 
his experience with 8 patients, and a few years later in 1970 reports came from Japan 
of the continuous experience by Oi and Tagaki.
51, 52
 The procedure is now mainly done 
because of stones lodged in the bile ducts or due to benign or malignant strictures both 
in the bile or pancreatic duct but is also effective in the treatment of ductal leaks of 
different origin. A 90
o
 side-viewing duodenoscope is brought down to the duodenum 
where the papilla of Vater is visualised with this structure defining the end of the bile 
and main pancreatic duct. A catheter with a guide wire is inserted through the papilla 
and the sphincter of Oddi into either the bile or pancreatic duct which can sometimes 
be very difficult to achieve. If the guide wire cannot pass the papilla, a pre-cut 
papillotomy with a needle sphincterotome could be tried in order to facilitate insertion 
of the guide wire. The ducts are visualised either by injecting contrast medium which 
could reveal fluoroscopic images of any existing pathology or by direct visualisation 
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by a “scope through the scope” previously called “mother-and-baby” scope. After 
cutting the papillary circular muscle of the sphincter of Oddi 
(sphincterotomy/papillotomy) using electric current and/or dilation with a balloon, 
stones can be evacuated or stents of different designs and materials (plastic or 
metallic) can be inserted to relieve bile stasis. It is also possible to use tissue forceps or 
a brush to sample tissue for histologic diagnosis.  
PEG insertion 
PEG was first described in a paediatric and adult population as a less traumatic 
procedure than open surgery for the insertion of a feeding catheter through the 
abdominal wall into the stomach.
53, 54
 The main reason for using a PEG is for meeting 
nutritional needs when the oral route proves insufficient, but sometimes the purpose is 
drainage of the stomach and the gastrointestinal tract e.g. in patients with chronic 
bowel obstruction due to abdominal spread of various malignancies.  
There are three main types of PEG procedures. The “pull” type described by Gauderer 
and Ponsky, technique described below, is the easiest to perform and the most 
commonly used. 
53
 The second type is the Sacks-Vine “push” gastrostomy where the 
dilator-tipped catheter is pushed down through the oesophagus over a guide wire and 
out through the abdominal wall. 
55
 The third type is the introducer PEG (Russell 
gastrostomy), sometimes wrongly referred to as the “push PEG”, where the stomach 
usually is attached to the abdominal wall by percutaneous sutures or suture anchors 
and the PEG catheter is introduced directly through the abdominal wall into the gastric 
lumen, guided by endoscopy, fluoroscopy, or ultrasound.
56
 The introducer PEG has a 
lower reported infection rate but is technically more demanding to insert and more 
expensive than the pull PEG.
57
 . This procedure, as well as the other described PEG-
procedures described above, could be laparoscopy assisted to reduce the risk of 
damaging intraabdominal organs.
58, 59
 
When using “stay” or anchor sutures it is possible to directly insert a button-type 
gastrostomy (skin level design) at the first intervention which often is the norm in 
children needing a gastrostomy. The button gastrostomy has a refillable balloon or an 
expandable mushroom stopper on the inside and usually a one-way valve to stop back 
flow when the button is opened for usage. See 
Figure 3. 
 
Figure 3. A Mic-Key
®
 “button PEG” made of 
silicone.  
Reproduced by kind permission of MEDA AB, Solna, 
Stockholm, Sweden. 
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The PEG catheter is usually changed when it no longer functions, but due to foul smell 
and dark staining caused by fungal biofilm overgrowth, which also seems to be 
involved in making the silicone catheter brittle,
41, 60
 the catheter is often changed every 
6 to 12 months. In paper III and IV of the present thesis, a standard silicon wire-
reinforced 20 Charrière (=20 Fr) Bard
®
 FasTrac
™
 (Bard Norden AB, Helsingborg, 
Sweden) pull PEG catheter was used in all cases. 
 
Pull PEG technique: This intervention is often conducted by an endoscopist involved 
in the gastroscopy and a surgeon performing the PEG insertion, but could be done by 
the endoscopist alone performing both procedures with the assistance of an endoscopy 
assistant. Antibiotic prophylaxis is recommended, usually as an intra-venous second 
generation cephalosporin (cefuroxime) given before the procedure. Insufflation of air 
brings the stomach wall closer to the inside of the abdominal wall and pushes the 
transverse colon downwards and off the stomach. Thereafter, the endoscopic light is 
usually seen through the abdominal wall and by pointing a finger against the 
abdominal wall and visualising the indentation inside the stomach, the best point for 
PEG-placement can be deduced. If these positioning steps are not deemed satisfactory, 
a safe passage to the stomach through the abdominal wall cannot be guaranteed, and 
the procedure should be cancelled. In such cases it is safer to perform the gastrostomy 
using laparoscopic assistance
58
 or by open surgery, a modified version of the Witzel 
gastrostomy first performed in 1891.
4
 If, however, the positioning steps are acceptable 
the pull PEG procedure continues by anaesthetising the planned introduction channel 
in the abdominal wall with local anaesthesia (1% lidocain) and the thin 5 cm long 
injection needle protruding into the stomach is visualised through the scope. A small 
skin incision (about 8 mm) is made adjacent to the injection needle, where also a 
longer, larger bore needle is inserted through which a thread is entered. This thread is 
captured inside the stomach by the endoscopist using a loop instrument put down 
through the working channel of the endoscope and the thread is thereafter pulled up 
together with the endoscope. The PEG-catheter (see Figure 2, page 19) is attached to 
the oral end of the thread and by pulling on the abdominal end, the catheter is gently 
pulled down through the oesophagus and out through the abdominal wall. The catheter 
has an inner flange and on the outside a special adapter preventing the catheter from 
moving inwards. The PEG-procedure usually takes 10-15 minutes to complete.
57
 The 
catheter can be used for enteral feeding after 2 hours. The success rate of PEG 
insertion is usually ≥90%.61 
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  General endoscopic complications 
All endoscopic procedures in the upper gastrointestinal tract carry the risk of the most 
feared and potentially lethal complication, i.e. perforation.
62
 When the scope is 
introduced into the oesophagus the first part is carried out more or less blindly and if 
an unsuspected anatomical abnormality or a pathological condition, e.g. a 
diverticulum, cancer or severe inflammation, is undiagnosed before endoscopy, a 
perforation might easily occur. Fortunately these perforations are very rare when 
diagnostic procedures are done with flexible endoscopes (0.1%), but the risk is higher 
when using rigid endoscopes (1.0%). This risk increases when interventional 
procedures in the oesophagus are performed, such as dilatation of strictures and 
foreign body removal.
63, 64
  
To reduce the risk of reflux-induced aspiration during and immediately after the 
endoscopy, the gastric contents should preferably be emptied from the start. Cardiac 
arrhythmias are seldom seen but occur occasionally in patients with known cardiac 
disease, although lethal arrhythmias, caused by defective electrical equipment, have 
been reported.
65
  
Use of intravenous sedation with midazolam during the procedure and sometimes 
potent opioid analgesics may introduce a risk of hypoxia when the stimulating effect 
of the endoscopy ends. Standardised supervision of the patient at the endoscopy 
department and at the wards is therefore necessary during the first hours after the 
procedure until the patient is fully awake.  
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Procedure-specific complications 
Oesophageal stenting: Stenting of the oesophagus in malignant disease has been 
proven effective for palliating dysphagia,
66
 but is not without risk of complications. 
Procedure-related mortality, mainly due to aspiration (2.3%) or oesophageal rupture 
(1%), has been reported.
31, 66
 After stent deployment, a more or less severe chest pain 
or foreign body sensation occurs in the majority of cases during the first few days of 
stent expansion,
31, 67
 and this often has to be controlled by strong analgesics, e.g. 
opioids.
68
  
The rapidly increasing incidence of adenocarcinoma of the oesophagus during the last 
three decades contributes to the fact that a majority of oesophageal cancers are located 
distally.
29, 69, 70
 This means that the stents often have to extend into the stomach, which 
predisposes gastrooesophageal reflux,
31, 35, 36
 with a risk for reflux-induced severe 
esophagitis and aspiration pneumonia. Stent migration is another problem, especially 
when stents pass the oesophagogastric junction, where the distal part of the stents is 
much less anchored by the surrounding tissue.
29, 31
 Stenting induces bleeding in 5-6.3% 
of the cases, often caused by the tumour itself,
31, 68
 or in the gastric mucosa if the stent 
protrudes into the stomach.
29
 If the stricture is very tight there is sometimes a need to 
dilate the tumour with e.g. a Savary-Gilliard
®
 Dilator or a balloon dilator to pass the 
tumour with the stent delivery system which usually has a diameter of about 5 to 13 
mm. Such dilatation introduces a risk of perforation. Stent expansion is rarely followed 
by perforation, but could sometimes develop into an airway fistula.
31
 Due to the 
anatomic configuration of the oesophagus in the mediastinum, tumour growth near the 
trachea or the left main bronchus could give rise to airway compression and acute 
dyspnoea caused by stent expansion. If this is anticipated, e.g. on pre-stent computer 
tomography, the airway should be stented first. 
ERCP: Procedure-related mortality after ERCP is ≤1%.71 Free duodenal perforation 
during ERCP is rare (0-2%) but once they occur mortality rate can be high (16-18%).
72
 
A retroperitoneal perforation, most often due to the sfincterotomy, is less dangerous 
and could heal with conservative treatment, but if peritonitis develops, surgical 
treatment is necessary.
73, 74
 The most common complication after ERCP is acute 
pancreatitis which occurs in about 2-7% of the cases.
12, 71, 75-77
 The majority of these 
cases subside after 1-2 days, but the pancreatitis could develop into a severe form with 
septicaemia, systemic inflammatory response syndrome (SIRS) and perhaps multi-
organ dysfunction syndrome (MODS) needing intensive care treatment. Within such 
severe cases the mortality rate is high (up to 67%) and the morbidity is serious.
78
 
Bleeding after papillotomy or dilatation is seen in <1%,
12, 71
 but can be dangerous 
because of the initial absence of symptoms in the sedated patient. Ascending infections 
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into the biliary ducts after ERCP are reported in up to 5% ,
71
 and antibiotic prophylaxis 
is therefore often used especially if there is pre-ERCP bile stasis. 
PEG: Procedure-related mortality is low (0-2%) 54, 79-81 but, as the typical PEG-patient 
often has a heavy burden of co-morbidity apart from the reason for having PEG, a 30-
day mortality of 8-28%,
82-85
 and a 6-month mortality of 44%, 
86
 have been reported 
among in-hospital patients. Suggested risk factors for early mortality after PEG 
include hypoalbuminemia, high CRP, diabetes, chronic obstructive pulmonary disease, 
advanced cancer stage, severe neurological disease such as stroke, cachexia/low BMI, 
age, mechanical ventilation and dialysis.
82, 86-88
 PEG is a technically an easy procedure 
to perform, but it is followed by a substantial risk of a number of side effects, where 
peristomal infection is seen in up to 32% if no antibiotic prophylaxis is used.
14, 89-92
 
These infections could cause pain, prolonged hospitalisation and increased costs,
93
 but 
they also have the potential of developing into a more severe variant of necrotising 
fasciitis with high mortality.
94
 Both patient-related factors (e.g. obesity, diabetes, 
malnourishment, smoking and cortisone medication) and surgery-related factors (e.g. 
inadequate aseptic technique, too short cutaneous incisions, the catheter bolster placed 
too tightly against the skin or low PEG-procedure surgeon volume) may contribute to 
the development of PEG-related infections.
81, 89, 95-99
 Aspiration pneumonia due to 
reflux after initiation of feeding through the PEG is a well-known risk with a reported 
occurrence of 23%.
100
 Less common problems are bleeding (<4%) from the stomal 
tract or ulcerations due to a mechanical effect of the PEG-catheter on the gastric 
mucosa, which rarely perhaps could lead to an aortogastric fistula, but the most 
common cause of bleeding seems to be reflux-induced esophagitis.
101-105
 Other more or 
less infrequent complications are buried bumper syndrome,
106
 peritonitis due to 
leakage of gastric contents alongside the PEG catheter (2.3%),
90, 107, 108
 accidental 
removal of the PEG catheter,
109
  colo-gastro-cutaneous fistula,
110
 gastric volvulus,
111
 
subcutaneous emphysema,
112
 and intra- or transhepatic PEG placement.
113
 A rare but 
important problem is the risk of tumour seeding to the catheter tract in the abdominal 
wall in patients with throat cancer (up to 1% of cases).
114, 115
 This problem is very 
rarely described in oesophageal cancer, perhaps because these patients have a very 
short survival rate due to advanced disease.
116
 Leakage around the catheter after PEG 
is common (up to 78%) and is reported as “problematic” in up to 39% of patients with 
long-term PEG.
117
 Gastric outlet obstruction caused by dislocation of the catheter and 
internal bumper into the duodenum where an occlusive effect may occur,
118
 but it 
seems to be less common after PEG than after the Witzel gastrostomy, which might be 
explained by a better catheter fixation device included in modern PEG-sets, and 
perhaps by nowadays better informed patients, relatives or patient carers. Post-PEG 
pneumoperitoneum is found in up to 30% of patients, but is usually without clinical 
significance.
106
 Long-term PEG users are also constantly reminded about their disease 
by the catheter, and this could negatively affect their HRQL.
117
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Aspects of complications and risk factors 
addressed in this thesis 
 
I. The impact of anti-reflux stenting on HRQL in patients with incurable 
distal oesophageal cancer: 
The main symptom in oesophageal cancer is progressive dysphagia, which affects 
nearly all patients. Since a majority of oesophageal cancers are situated distally, and in 
more than 50% of cases, are inoperable on diagnosis,
119
 palliative stenting across the 
gastrooesophageal junction is common in oesophageal cancer patients. This 
compromises the anti-reflux function of the lower oesophageal sphincter,
36
 and 
introduces a risk of gastric reflux induced esophagitis and aspiration pneumonia with 
possibly severe consequences in the daily lives of the patients. Therefore, stents with 
an anti-reflux valve have been introduced.
120-122
  A few randomised studies comparing 
antireflux stents with conventional stents have shown conflicting results regarding 
their efficacy in counteracting reflux, but they seem to have equally good effect 
against dysphagia.
35-38
  When treating incurable oesophageal cancer patients who are 
known to have a short survival and where different palliative procedures do not 
materially prolong survival, the main purpose should be to improve HRQL during the 
remainder of the patient’s life. Thus, the results of different palliative strategies on 
HRQL found in randomised trials should be used in decision making.
123, 124
 
In paper I, we randomised patients with inoperable distal oesophageal cancer or cardia 
cancer to anti-reflux or conventional stents and assessed the effect on baseline HRQL 
at follow-up using self-administered questionnaires developed by EORTC.
46, 47
 
 
II. Prophylaxis against post-ERCP pancreatitis:  
A frequently used definition of post-ERCP pancreatitis is 1/ abdominal pain >24 hours 
after ERCP and 2/ pancreatic enzyme amylase or lipase levels >3 times the upper 
normal limit. Post-ERCP elevation of amylase in serum occurs in 25-40% of cases,
75, 
76, 125-127
 and post-ERCP pancreatitis occurs in 2-7%.
12, 71, 75-77, 125
 The wide range 
between reported frequencies could be due to different patient populations, indications, 
procedures, endoscopic skill, and different definitions of outcome.
127
 Risk factors for 
developing pancreatitis after ERCP include young age, female sex, previous 
pancreatitis, dysfunction of the sphincter of Oddi, and procedure-related factors, such 
as difficult cannulation of the bile and pancreatic ducts, experience of the endoscopist, 
pancreatic duct manipulation or injection of contrast media, sphincterotomy, and use 
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of SEMS instead of plastic stents for bile decompression.
12, 71, 77, 127, 128
  Much effort 
has been devoted to identifying preventive measures against post-ERCP pancreatitis. 
Several clinical trials addressing many different pharmacological preparations have 
been conducted, but so far there is no established pharmacological prophylaxis even 
though some drugs have shown some promising effects.
129-131
 Non-pharmacological 
means of prevention could perhaps be achieved by temporary stenting of the 
pancreatic duct after ERCP. 
132, 133
   
There is, however, support for the new hypothesis that angiotensin II type 1 receptor 
blockers (ARB) could prevent the development of pancreatitis and/or pancreatic 
hyperenzymemia after ERCP. Angiotensin II is the active product in the biochemically 
complex renin-angiotensin system which is said to regulate blood volume, electrolyte 
homeostasis, and vascular tone, but also to have trophic and pro-inflammatory 
characteristics.
134
 Another finding is that there is not only a systemic component, but 
also a local tissue component which seems to modulate cell growth, cell 
differentiation, and intercellular communication.
134
  Later research has found that the 
renin-angiotensin system comprises both a pressor and a depressor function in vascular 
tone regulation and cellular signalling.
134
 Moreover, acute pancreatitis activates a local 
pancreatic renin-angiotensin system, mainly localised in the vascular endothelium and 
the pancreatic duct epithelium, as well as the systemic renin-angiotensin system.
135, 136
 
Experimental research has shown that the angiotensin II type 1 receptor and 
angiotensinogen are highly expressed in inflamed pancreatic tissue, leading to local 
vasoconstriction with hypoxia, acidosis and inflammation.
137
  
Administration of angiotensin II increases the secretion of pancreatic enzymes,  and 
this increased secretion can in turn be blocked by the commonly used antihypertensive 
drug, ARB losartan (Cozaar
®
).
137, 138
 Moreover, losartan can prevent experimentally 
induced acute pancreatitis in rats.
138-140
 Furthermore, a recent case-control study from 
our group indicated a decreased risk of acute pancreatitis among patients treated with 
ARB.
141
   
Paper II describes a clinical trial testing whether losartan prevents pancreatic 
hyperenzymemia after ERCP. As hyperenzymemia is linked to acute pancreatitis and 
if this increase in enzyme levels could be reduced by losartan a larger study would be 
conducted to see if losartan also could reduce the frequency of post ERCP pancreatitis. 
 
III. Antibiotic prophylaxis during PEG:  
Several randomised trials and meta-analyses have shown that antibiotic prophylaxis 
reduces the absolute risk of peristomal infection by between 14-17.5%, corresponding 
to 6 patients having to be treated in order to avoid one infection (number needed to 
treat = 6).
142-145
 Other means of reducing the risk of peristomal infection are to use the 
introducer PEG technique or to pull down the PEG catheter inside a plastic covering. 
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These techniques bypass the bacteria in the mouth, throat, and oesophagus.
57, 146, 147
  
They are, however, more complicated to perform than the simple pull PEG technique 
and involve a substantially higher cost. Therefore, the pull PEG technique is still the 
most frequently used.  
A single dose of a second generation cephalosporin (cefuroxime) is often used as 
antibiotic prophylaxis,
148
 since cefuroxime has a documented good effect on the 
bacteria commonly found in the upper gastrointestinal tract.
149, 150
 Normally, 1.5 grams 
of cefuroxime is given intravenously at the ward about 1 hour before the planned 
intervention, but sometimes this is forgotten or postponed which could delay the PEG 
procedure. Cefuroxime is also comparatively expensive, has a short biological half-life 
(1.5 hours), is given unnecessarily whenever the PEG procedure is unsuccessful (5-
10%),
61, 79
 and can contribute to pseudomembranous enterocolitis induced by 
Clostridium difficile bacteria after only a single dose.
151, 152
  
We considered whether the enteral solution of sulphamethoxazole/trimethoprim, given 
in the PEG catheter directly after the catheter insertion, could be at least as effective as 
the standard treatment with cefuroxime. If this was the case there are several 
advantages to be gained, namely: faster, easier administration, longer biological effect 
(biological half-life 10 and 11 hours), avoidance of unnecessary treatment when the 
PEG insertion fails, reduced cost and, probably, better bacterial ecology.  
In paper III we tested whether sulphamethoxazole/trimethoprim was at least as good as 
standard antibiotic prophylaxis.  
 
IV. Risk factors for mortality and peristomal infections after PEG: 
Patients considered for PEG have in general an increased risk of complications, due to 
the malnutrition requiring PEG placement and the disease causing the malnutrition, as 
well as a high occurrence of co-morbidities associated with these patients, such as 
diabetes, cardiovascular disease and cancer. Knowledge of risk factors that are linked 
with a particularly increased risk of poor outcomes after PEG insertion is essential 
when selecting and advising patients for PEG placement. 
There are alternatives to PEG, such as nasogastric and intravenous catheters for 
nutrition, which might be preferable if certain high-risk patients are identified. 
Previous research has indicated that advanced age, low serum albumin levels, high 
CRP levels, low BMI, and co-morbidities might be risk factors for complications after 
PEG.
82, 86-88, 153-156
 Low albumin and raised CRP seem to be strong risk factors for 
early mortality and post-operative infection in cancer patients.
157-161
 High CRP is 
associated with inflammatory states, which in turn could contribute to cachexia.
162
 
Thus, low albumin and high CRP are both linked with malnutrition. These potential 
risk factors for PEG complications have, however, not been established and are 
therefore not considered in the clinical decision-making.
88
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In paper IV we therefore evaluated potential risk factors for early mortality and 
peristomal infection after PEG. 
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Aims of the studies 
The overall aim of this thesis was to gain knowledge of how to modify endoscopic 
interventions so that fewer complications and morbidities occur.   
Specific aims: 
●  To evaluate whether the anti-reflux stent Esophageal Z-stent® with a Dua Anti-
reflux Valve improves the HRQL in patients with incurable distal oesophageal or 
cardia cancer, as compared to conventional stenting. (Paper I) 
● To assess whether the antihypertensive angiotensin II receptor blocker losartan 
prevents pancreatic hyperenzymemia after ERCP. (Paper II)  
● To estimate whether enteral sulphamethoxazole/trimethoprim antibiotic prophylaxis 
given in the PEG catheter after the procedure can replace standard treatment in the 
prevention of peristomal infections. (Paper III) 
● To identify risk factors for early mortality and peristomal infection after PEG. 
(Paper IV) 
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Patients and methods 
Paper I 
Design 
A randomised, single-blind, clinical, multicentre trial, comparing an anti-reflux 
oesophageal stent (ARS) with conventional stents (CS) in relation to measures of 
HRQL, was conducted at 11 centers in Sweden during the period 1 September 2003 to 
31 December 2007 with follow-up until 31 March 2008. The randomisation was 
conducted at The Regional Oncological Center at Karolinska University Hospital, 
Solna. The patients were unaware of the type of stent inserted. We hypothesised that 
an ARS, compared to a CS in the distal oesophagus, would be followed by a better 
HRQL as measured by the validated HRQL questionnaires EORTC QLQ-C30 and the 
QLQ-OES-18.  
Patients  
Patients considered for randomisation were those with histologically verified 
inoperable cancer of the distal oesophagus or cardia with dysphagia (could at best eat 
semisolid food) with a clinical need for a stent that would be assumed to pass through 
the cardia. Moreover, the anticipated survival should be at least one month, and the 
patients should have no other malignant disease.  
Stent types 
The test stent was a covered Oesophageal Z-stent
®
 with a Dua Anti-reflux Valve 
(Wilson-Cook Medical, Winston Salem, NC, USA) which is a self-expanding, 
covered, stainless-steel mesh stent with an 80 mm long antireflux plastic sleeve 
attached to the distal part of the stent (Figure 4). The body diameter was 18 mm and 
there was a partly uncoated flared upper part with a diameter of 25 mm. These stents 
were available in lengths of 8 to 14 cm. The CSs used were of three types (chosen 
according to local hospital tradition): a partly covered stain-less steel Z-stent
®
 without 
anti-reflux sleeve (Wilson Cook Medical Inc, Winston Salem, NC, USA) with same 
diameters as above (see Figure 4), an UltraFlex
®
 single-strand nitinol (nickel titanium 
alloy) wire stent with a body diameter of 18 mm and flared uncovered ends of 23 mm 
(Boston Scientific, Natick, MA, USA), or a Wallstent
®
 with partial silicone covering 
(Boston Scientific) and 18 mm shaft diameter and flared ends of 23 mm. The reasons, 
for the decision to accept different CSs in the trial were 1/ to get maximum inclusion, 
34 
since several centres preferred to use “their” type of CS for these patients, and 2/ 
studies have not shown any major differences between different covered CSs.
27, 28
 
 
Figure 4. Oesophageal Z-Stent with Dua Anti-Reflux valve, a 80 mm long plastic 
collapsible sleeve connected to the distal part of the stent (left, ARS) and Oesophageal 
Z-Stent, (right, CS), Cook® Medical Inc. 
 
Follow-up 
The patients were scheduled for revisits at one and three months after stent insertion 
and thereafter every third month until death or end of study period. At baseline and at 
these revisits the HRQL scores were assessed with the validated standardised 
questionnaires designed for self-administration (EORTC QLQ-C30 and QLQ-OES18), 
on general and oesophageal cancer specific symptoms and functions, which the 
patients also had completed at baseline. Adverse events were noted. 
Statistical methods 
In the sample size calculation we assumed that patients with ARS would have 30% 
better results regarding HRQL, and with 80% power and alpha 0.05, we calculated a 
total sample size of 210 patients. All HRQL scales and single-item scores from the 
questionnaires were converted into a score between 0 and 100, and mean scores and 
their 95% confidence intervals were calculated in accordance with the EORTC 
manual.
48
  Previous research has shown that a difference of at least 10 in mean scores 
between follow-ups or between comparison groups may be considered a clinically 
relevant difference.
49, 163
 Clinically relevant mean score differences between baseline 
and follow up were formally tested for statistical significance with the Mann-Whitney 
test for continuous variables. The Chi-square test for dichotomous variables was used 
when comparing clinical details between the treatment groups. Kaplan-Meier estimates 
35 
were calculated to assess differences in survival between groups, and tested with the 
log-rank test. 
 
Paper II 
Design 
A triple-blind, placebo-controlled randomised trial was performed to evaluate the 
effect of 50 mg of the angiotensin II receptor blocker losartan on hyperenzymemia 
after ERCP. Two hospitals participated and included patients during the period from 
1May 2006 to 31 October 2008. The capsule was given 1 hour before ERCP. The 
patients, endoscopists, and the evaluators were all blinded to the treatment given. The 
capsules in the different treatment groups were identical in appearance. The code 
identifying the capsules and patients were kept with the study administrator, who did 
not participate in the treatment of the patients.  
Patients 
Patients considered for inclusion were those who were older than 18 and referred for 
first time ERCP or in whom >1 year had passed since the last ERCP.  Patients not 
considered for inclusion were those with on-going acute or chronic pancreatitis, 
elevated amylase or lipase levels, users of any ARB or ACE inhibitor medication, 
kidney insufficiency, bilateral renal arterial stenosis, pregnancy, or severe predefined 
co-morbidity such as sepsis, disseminated intravascular coagulation, circulatory 
collapse, severe dehydration, hypovolemia, or liver failure.  
ERCP procedure 
The procedure is done with the same sedation method as in other endoscopies with the 
patient in the left lateral position or with general anaesthesia with the patient often in 
the supine position. When the tip of the duodenoscope has reached the second part of 
the duodenum the endoscope is made stiffer by rotating it about 90
o
 to the right and at 
the same time reducing the inserted length of the scope. This shortening of scope 
length inside the patient makes manoeuvring in the duodenum easier. Otherwise it is 
done as described on page 22. If needed, glucagon or butylscopolamine could be given 
to reduce intestinal motility and relax the sphincter muscle of Oddi, which may make 
it easier to intubate the papilla. 
Post-ERCP measurements 
Blood tests for analyses of amylase, lipase and glucose were taken at baseline, and at 
1, 4 and 24 hours after ERCP. Blood pressure and pulse rate were analysed at baseline, 
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and at every hour up to 6 hours and 24 hours after ERCP. Any abdominal pain was 
registered at baseline and 24 hours after ERCP. 
Statistical methods 
The sample size calculation showed that a total of 76 patients would be needed, on the 
assumption that hyperenzymemia after ERCP would decrease from 40% to 10%, with 
80% power and alpha 0.05. The main analysis strategy was intention-to-treat. 
Categorical variables were tested with the Chi squared test or the Fishers exact test, 
and for continuous data we used an analysis of variance (ANOVA). To adjust for any 
imbalance of potentially confounding factors occurring in spite of randomisation, we 
used a multivariable logistic regression model with adjustment for possible 
confounders such as sex, age, BMI, history of pancreatitis, study centre and duration 
of procedure, when estimating the relative risk of hyperenzymemia. 
 
Paper III 
Design 
A single centre, double-blind randomised clinical trial was conducted to compare 
standard antibiotic prophylaxis (1.5 grams cefuroxime given intravenously before PEG 
insertion) with a new strategy: 20 ml oral solution sulphamethoxazole/trimethoprim 
injected via the PEG catheter immediately after the procedure, regarding the frequency 
of peristomal infection. Patients and the nurses who evaluated any occurrence of 
complications at follow-up were blinded to the treatment given.  
Patients 
Patients referred for PEG, at Karolinska University Hospital, without exclusion criteria 
and who were able to give informed consent, were included during the period from 3 
June 2005 to 31 October 2009.  
Follow-up 
Specially trained nurses evaluated whether the patients had any complications, with 
special focus on peristomal infection at follow-up within 14 days after PEG insertion. 
If there was a larger red zone around the catheter than usual, suppuration, and pain on 
palpation in the immediate vicinity of the PEG catheter, a clinical infection was 
diagnosed. Haemoglobin, CRP and white blood cell count were analysed and a 
bacterial culture was taken from the stoma.  
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Statistical methods 
The primary objective was to assess non-inferiority of 
sulphamethoxazole/trimethoprim compared to cefuroxime with a pre-specified non-
inferiority limit of 15%. The difference in the proportion of infection between the 
groups was estimated and the corresponding two-sided 95% confidence interval (CI) 
was calculated. Non-inferiority of the test treatment
 
would be achieved if the upper 
limit of the 95% CI was smaller than the pre-specified non-inferiority margin of 15%. 
The main strategy was intention-to-treat analysis, which evaluated all randomised 
patients regardless of whether or not they received a PEG and were followed up. 
Moreover, a per-protocol analysis was performed as a sensitivity test.  
 
Paper IV 
Design 
A prospective cohort study was conducted at the Karolinska University Hospital 
during the period 2005-2009. Follow-up within 14 days was conducted to evaluate the 
importance of 6 pre-determined potential risk factors, registered at baseline, for short-
term mortality and peristomal infections after PEG. The potential risk factors were: 1/ 
advanced age (≥65 years or younger), 2/ low BMI (<18.5 kg/m2 or higher), 3/ low 
albumin level (<30 g/L or higher), 4/ high CRP level (≥10 mg/L or lower), 5/ 
indication for PEG (cancer, stroke, neurological disease, dementia, or other), and 6/ 
co-morbidity (cancer, cardiovascular disease, neurological disease, diabetes, or other). 
Primary outcomes were mortality within 30 days and peristomal infection within 14 
days after PEG insertion. 
Patients 
All patients referred for PEG at Karolinska University Hospital in Solna were eligible 
for inclusion. At baseline, body height and weight were measured and BMI was 
calculated, blood samples (CRP and albumin) were taken, and the indications for PEG 
and co-morbidity were registered. 
Follow-up 
The follow-up procedure was identical to that in paper III above. 
Statistical methods 
We used a logistic regression model to estimate odds ratio with 95% confidence 
interval regarding risk of peristomal infection within 14 days after PEG. Since we did 
not have the exact starting dates for such infections, Cox regression was not possible. 
A Cox proportional hazards model was used to estimate hazards ratio with 95 % 
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confidence interval to evaluate the risk of mortality within 30 days after PEG. 
Adjustments were made for age, sex, albumin, co-morbidity index (0-3 co-
morbidities), tobacco smoking, and BMI. A test for possible biological interaction 
between low albumin and high CRP was also performed. 
 
Ethical consideration 
All the studies (I-IV) were approved by the local ethical committee. Study II and III 
were approved by the Swedish Medical Products Agency. In papers I and II, written, 
informed, signed consent was obtained from each participant before inclusion. In 
paper III the patients were given oral and written information about the study before 
they agreed to participate and this was documented in the journal and, in paper IV, the 
patients, their care givers or attending relatives were given written and oral 
information about the data collection and its use for research purposes.  
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Results 
Paper I 
Study participants and procedures 
A total of 72 patients were randomised, but 5 patients were excluded due to 
misclassification, and 2 patients were excluded due to rapidly progressive disease. 
These exclusions contributed to the skewness of allocation, since 6 of the 7 excluded 
patients had been randomised to the ARS group. A flow chart of the study is shown in 
Figure 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Flowchart of all randomised patients. ARS=anti-reflux stent, 
CS=conventional stent. 
 
The complication rate within one month did not differ significantly between the two 
groups, although the total number of complications was higher in the CS group while 
more patients had complications in the ARS group. No procedure-related death was 
noted. As expected, males dominated in both groups. The median survival in the ARS 
3 months 
1 month
Baseline 
72 randomised 
patients 
28 patients treated 
with ARS  
37 patients treated with 
CS  
5 patients died,  
4 patients too ill to 
respond to the 
questionnaires 
 
11 patients died, 
5 patients too ill to 
respond to the 
questionnaires 15 patients responded 
at 1 month follow-up 
19 patients responded 
at 1 month follow-up 
2 patients not stented 
5 patients not stented 
within trial 
5 patients responded at 
3 months follow-up 
9 patients responded at 
3 months follow-up 
5 patients died, 
5 patients too ill to 
respond to the 
questionnaires 
 
6 patients died,  
4 patients too ill to 
respond to the 
questionnaires 
 
24 patients responded 
to baseline assessment 
35 patients responded 
to baseline assessment 
2 patients too ill to 
respond to the 
questionnaires  
4 patients too ill to 
respond to the 
questionnaires 
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and CS group was 63 and 70 days respectively. A Kaplan-Meier curve of probability 
of survival is shown in Figure 6, visualising the short life expectancy, which was equal 
in the comparison groups.  
 
Figure 6. Survival curve, after stenting, in 65 randomised patients treated with an 
antireflux stent or a conventional stent. 
 
HRQL 
Among the 34 patients who completed the HRQL questionnaires both at baseline and 
at one month, there were some clinically relevant differences in HRQL between 
treatment groups but no statistically significant differences. Dysphagia and eating 
difficulties improved to a greater degree in the CS group, but unexpectedly the reflux 
symptoms increased in the ARS group. Oesophageal pain increased in both groups, 
whereas speech problems only increased in the CS group. At 3 months there were only 
14 patients able to answer the questionnaires, and those in the CS group had 
deteriorated more in physical and social function and fatigue compared to the ARS 
group.  
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Paper II 
Study participants and procedures 
A large proportion of patients were disqualified (n=215) due to the exclusion criteria, 
leaving 76 patients for final analysis. Of these, 38 patients were randomised in each 
group. Most of the excluded patients were in the category “ERCP in less than a year 
before inclusion” (n=142). Basal characteristics showed equal distribution in the two 
groups, apart from men being somewhat overrepresented in the losartan group. Biliary 
duct sphincterotomy was used slightly more often in the losartan group (n=27) than in 
the placebo group (n=24). The number with cannulation difficulty was equally 
distributed between groups, as were radiological findings and patients requiring stents 
in the bile ducts. However, there were more pancreatic injections of contrast media 
and sphincterotomies in the losartan group than in the placebo group. The mean blood 
pressure at baseline was similar in both groups but, at 24 hours after ERCP the mean 
blood pressure was lower in the losartan group, which could be an indication of the 
pharmacological effect of losartan. 
Pancreatic enzyme levels 
Hyperenzymemia was defined as more than 3 times the upper normal value of amylase 
or lipase at 24 hours or more after ERCP. Hyperenzymemia was registered in 9 (24%) 
and 7 (18%) patients in the losartan group and in the placebo group, respectively. The 
multivariable regression model did not reveal a decreased risk of hyperenzymemia in 
the losartan group as compared to the placebo group (OR, 1.6; 95% CI, 0.3 to 7.8). 
There were no major differences between enzyme response of amylase or lipase after 
ERCP. Mild acute pancreatitis (according to the Atlanta criteria)
164
 occurred in 5 
(13%) patients in the losartan group and 4 (11%) patients in the placebo group. No 
cases of severe acute pancreatitis were seen. 
 
Paper III 
Study participants and procedures 
During the study period, 535 patients were referred for PEG. Of these, 301 were 
unable to give informed consent. Basic characteristics were evenly distributed, except 
for fewer women in the cefuroxime group and more oesophageal cancer patients in the 
sulphamethoxazole/trimethoprim group. In total, 118 patients were randomised to the 
cefuroxime group and 116 to the sulphamethoxazole/trimethoprim group. The PEG-
procedure was impossible to accomplish for 10 % of the patients in each group. 
Moreover, 5 patients died before follow-up, 3 patients were lost to follow-up, 1 patient 
pulled out the catheter soon after insertion (without ensuing complication) and 1 
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patient received the wrong treatment. Thereafter, 100 patients in each group remained 
for the per-protocol analysis.  
Complications and infection 
No statistically significant differences were noted in the pre-determined definition of 
complications at follow-up, but there was a numerically higher frequency of 
peristomal infections in the standard cefuroxime group. We detected 10 infections in 
the sulphamethoxazole/trimethoprim group and 14 infections in the cefuroxime group. 
The proportion difference in the intention to treat analysis was -3.3% (95% CI, -10.9 
to 4.5%), which was well below the pre-determined non-inferiority limit of 15%. The 
per-protocol analysis supported the result of non-inferiority. The number of positive 
bacterial cultures, the white blood cell count, and CRP showed no statistical 
differences between the two groups. No allergic reactions were noted in either group. 
 
Paper IV 
Study participants and procedures 
The study cohort included 535 patients, of whom 51 were excluded because the PEG 
insertion failed. Figure 7 shows an overview of the study flow. 
Figure 7. Flowchart of the PEG and risk factors prospective cohort study. 
In 51 patients the PEG procedure 
failed 
20 patients died before follow-up 
535 patients referred for PEG 
9 patients were lost to follow-up 
453 patients were followed up at 2 
weeks 
A total of 58 (12%) patients died within 
30 days after PEG 
2 patients pulled out the PEG catheter 
before follow-up 
484 patients 
At 6 months 179 (37%) patients had 
died  
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The mean age was 66 years (SD 14) and there were slightly more males than females. 
The main indications were cancer (44%) and neurological disease including stroke 
(44%). 
 
Risk of early mortality 
There were 58 patients (12%) who died within 30 days after PEG insertion but there 
was no immediate procedure-related mortality. At 6 months 37% of the patients had 
died. The adjusted risk estimates for mortality within 30 days after PEG increased 
about 2-fold for age ≥65 years (HR, 2.26; 95% CI, 1.20 - 4.25), increased 3-fold for 
patients with an albumin level < 30 g/L (HR, 3.46; 95% CI, 1.75 - 6.88) and 3 fold 
increased for patients with CRP level ≥ 10 mg/L (HR, 3.47; 95% CI, 1.68 - 7.18). The 
risk of BMI < 18.5 kg/m
2
 was possibly, but not statistically significantly, increased 
(HR, 2.04; 95% CI, 0.97 - 4.31). The cancer patients had a trend toward lower risk of 
short-term mortality than stroke patients. The risk for 30-day mortality tended to 
increase with a higher number of co-morbidities but this was not statistically 
significant. The combination of low albumin (<30 g/L) and high CRP (≥10 mg/L) 
levels was followed by a 7-fold increased risk of 30-day mortality, as compared to 
patients with albumin ≥30 g/L combined with CRP <10 mg/L (HR, 7.45; 95% CI, 2.62 
- 21.19). The absolute mortality rate in patients with this risk combination was 20.5%, 
compared to 2.6% in patients with normal values. A trend of biological interaction 
(effect modification) was noted with the combination of low albumin and high CRP, 
but this was non-significant. The effect of low albumin combined with high CRP on 
survival compared to patients with both values normal is illustrated in Figure 8. 
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Figure 8. 30-day survival curve comparing patients with combination of low albumin 
and high CRP with patients with combination of high albumin and low CRP. 
 
Risk of peristomal infection 
As 20 patients died before follow-up, 9 were lost to follow-up and 2 patients pulled out 
their catheters, 453 patients remained for evaluation of peristomal infection at 14 days 
after PEG insertion, see Table 1. Among these, 50 patients (11%) had a clinically 
detected peristomal infection. Low BMI (<18.5), low albumin (<30 g/L) level, and 
high CRP (≥10 mg/L) level each showed a non-statistically increased risk of infection. 
Co-morbidities and the number of these did not influence the risk. No biological 
interaction was noted for low albumin and high CRP regarding the risk of peristomal 
infection. 
 
Complications 
Apart from peristomal infection and mortality, we pre-defined five common 
complications about which patients often complain after PEG insertion. These 
symptoms were registered at follow-up at 2 weeks and 2 months (Table 1). Leakage 
and diarrhoea were as common as peristomal infection at the 2-week follow-up. At 2 
months, peristomal infection was reduced to nearly half the initial value (Table 1).  
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Table 1. Complications registered at follow-up after insertion of percutaneous 
endoscopic gastrostomy (PEG) catheter in 484 patients. One patient can have more 
than one complication. 
 2 weeks 
n=453* 
2 months 
n=370* 
Complications Number (%) Number (%) 
No complication 288 (64) 254 (69) 
Died before follow-up 20 (4) 85 (18) 
Elective extraction of PEG before follow-up 0 (0) 19 (4) 
PEG pulled out by the patient 2 (0) 0 (0) 
Leakage 43 (10) 30 (8) 
Diarrhoea 50 (11) 34 (9) 
Constipation 26 (6) 17 (5) 
Abdominal pain 57 (13) 16 (4) 
Fever 10 (2) 4 (1) 
Peristomal infection 50 (11) 23 (6) 
* Number of patients available at follow-up. At 2 weeks and 2 months, 9 and 10 patients 
respectively were lost to follow-up. 
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Discussion 
General methodological considerations  
The randomised clinical trial used in papers I-III, is considered in its best form to give 
the most valid data about new drugs or therapeutic procedures, but it must be designed 
in an ethical manner so the patients are not denied the best available treatment. The 
patients must also give their consent voluntarily and it is crucial that they understand 
the aims of the study. The trial must also be designed to assess what it is supposed to 
test. A superiority trial, which is the most common type, is typically conducted to 
show whether a new treatment is superior to the standard treatment. A non-inferiority 
study has the aim of proving whether the new treatment is at least as good as standard 
treatment (the new treatment has other benefits than better effect, e.g. lower price or 
easier administration).  
The blinded randomisation process (allocation by chance) reduces the risk of 
systematic errors, including known or unknown confounding. This can further be 
decreased by maximum blinding (of the patient, treating personnel and evaluator) of 
given treatment. To further decrease contamination of unpredictable factors distorting 
the true association between treatment and outcome, the sample size must be large 
enough to provide a random distribution of confounders and allow a statistical power 
good enough to secure clinically meaningful findings. Sometimes this has to be 
achieved by a multi-centre trial which could give better sample size and possibly 
external validity or generalisability. On the other hand, the different centres could 
make it difficult for the principal investigator to control the proper equal inclusion, 
treatment and data registration of patients. If a large enough sample size is too difficult 
to achieve, a pooled analysis of a collection of several randomised studies of similar 
design and topic can be performed, i.e. a meta-analysis, to achieve better power. Other 
ways of reducing confounding are by randomised stratification of known confounding 
factors or by using exclusion criteria. At the analytic stage of small trials, 
multivariable regression models with adjustment for possible confounders can be 
utilised to further minimise confounding.  
Randomised trials have also been said to sometimes show very conflicting results 
although the design is equal. This could be explained by different groups of patients 
and the validity and generalisability must be considered carefully.
165
 Intention-to-treat 
analysis is the recommended primary analytic procedure but if compliance is low a 
true effect might be missed by loss of power. Therefore a per-protocol analysis could 
be done as a sensitivity analysis. 
The cohort study design, analytical or descriptive, is an observational study in which 
study subjects with different exposure can be observed and followed regarding the risk 
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of developing an outcome over time. RCT is a type of study where the exposures are 
randomly assigned to the study subjects. There are, however, many exposures usually 
not possible to randomly designate to people, e.g. age, sex, ethnicity BMI, and 
smoking. The non-randomly assigned exposures age, BMI, albumin level, CRP, 
indication for PEG and co-morbidity studied in paper IV carry the risk of systematic 
bias, e.g. confounding, with regard to their association with the outcomes of mortality 
and peristomal infection. The statistical assessment in this type of study, therefore, has 
to use analyses to allow adjustments for potential confounding variables, which cannot 
be ignored as they can in a properly conducted randomised study of sufficient sample 
size where the known and unknown confounders are likely to be evenly spread across 
treatment groups. The number of outcomes of interest in RCTs and cohort studies are 
usually limited to one or two. The mortality and infection rate after PEG (paper IV), 
are rather common outcomes and the cohort was rather large making the interpretation 
more robust.  
It has been said that cohort studies have a tendency to overestimate treatment effects 
but this seems to be related to the design and it has been suggested that well designed 
cohort or case-control studies do not overestimate the association between exposure 
and outcome as compared to randomised studies.
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  Many cohort studies are 
conducted in retrospectively making control of confounding factors less accurate as 
compared to a more labour-intensive, time-consuming, prospective design. In paper IV 
we used a prospective cohort study design. 
 
Specific methodological considerations  
Paper I 
This is a randomised, single-blind, multicentre, superiority study comparing two 
different oesophageal stents. The population from which recruitment was made had 
been thoroughly defined regarding tumour localisation, stage, histology, operability, 
dysphagia grade and the clinical need for an oesophageal stent. The patients were 
blinded to which stent they received, but the endoscopist could not be kept blinded due 
to obvious differences in the stent delivery system and the need for assembling the 
ARS immediately prior to stenting. The calculated number of patients needed for 
inclusion over 3 years was far higher than the number of participants finally included, 
although as many as 11 centres were involved in an effort to maximise inclusion. 
Thus, the statistical power was less than expected. This could contribute to a risk of 
rejecting a true difference, i.e. of accepting a false null hypothesis (type 2 error).  
The inclusion rate declined significantly over time, probably partly due to a change in 
the indication for surgery to a more aggressive approach, competing trials regarding 
chemoradiotherapy, and due to recent publications, indicating no positive effect of the 
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more complex and time-consuming insertion of the ARS. All this led presumably to a 
decreased willingness to include patients in the study. Other explanations were that, 
due to the rapidly deteriorating health status of the inoperable oesophageal cancer 
patients, they often had difficulties in answering HRQL questionnaires, and their 
survival was much shorter than expected.
66
  
Multiple testing is a risk in HRQL research where many measures are assessed. To 
limit this source of false positive findings (type I error), we only tested differences of 
more than 10 points between measured time points.
49, 163
 We used the EORTC QLQ C-
30 and QLQ OES-18 questionnaires which are well validated and have shown 
acceptable reliability.
46, 167
 The questionnaires are used internationally, making 
comparisons possible, and they are also reliably translated, back and forth for testing 
of the validity of the translation, into different languages including Swedish. The 
evaluation of stent effects on HRQL was made by the patients filling in the EORTC 
questionnaires, without external interference by study and health personnel, in the 
ward or at home. The patients did not know what kind of stent they had received, 
making the results less flawed. Finally, the conclusions could have been distorted by 
the imbalance of patient inclusion from different participating centres, but the site 
distribution was even in comparison groups and nearly 80% of the stented patients 
came from three large-volume hospitals, counteracting the influence of such 
imbalance. 
Advantages of the study are the randomised design, the blinding of the patients to the 
inserted stent, and the use of validated and reliable instruments for measurement of 
HRQL. 
 
Paper II 
This study was triple-blinded (to patients, endoscopists, and evaluators), randomised, 
two centre, placebo controlled, superiority trial evaluating the effect of losartan on 
pancreatic enzyme levels 24 hours after ERCP. Since the study aimed at first time 
ERCP patients, an arbitrary limit of one year since last ERCP was chosen. This 
criterion excluded many patients, which contributed to the slow inclusion pace. The 
hypothetical gain was set at the assumption that the maximum noted rate in the 
literature of patients with post ERCP hyperenzymemia, i.e. 40%,
126
 would be reduced 
to 10% of hyperenzymemia in the treatment group. Any weak association would 
therefore not be detected. However, hyperenzymemia in this study was less common 
than expected, contributing to a limited statistical power. The rate of acute pancreatitis 
was, however, more common than expected, probably due to detection bias or perhaps 
to chance. The predefined dose of 50 mg losartan, which is a common starting dose in 
treatment of hypertension, was calculated from animal studies where a protective dose 
of losartan was found to be 0.2mg/kg.
138
 For practical and predetermined reasons, 
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losartan was given 1 hour before ERCP, while the peak concentration is about 3-4 
hours after administration, and perhaps 1 or 2 hours more for the more potent active 
metabolite of losartan. Speculatively, a longer latency interval between administration 
and ERCP could have given other results, but on the other hand, pancreatitis develops 
over the course of several hours. The blood pressure was lower at 24 hours after ERCP 
in losartan-treated patients, showing that the losartan dose had some pharmacological 
effect. 
Obvious strengths of the study were the maximum blinding, the identical capsules with 
active drug or placebo, the objective measurements of pancreatic enzymes, and the 
short follow-up. 
 
Paper III 
This was a double-blinded, randomised, single centre, non-inferiority clinical study 
with active controls including 234 patients, to elucidate whether 
sulphamethoxazole/trimethoprim is at least as good as cefuroxime in infection 
prophylaxis during the PEG procedure. Findings in the literature on the effect of 
antibiotic prophylaxis during PEG on peristomal infection frequency made us decide 
on clinical grounds on a non-inferiority level of 15%. In practical terms this means that 
<15% more infected patients in the co-methoxazole group could be accepted and still 
be labelled non-inferior to standard treatment. The primary outcome, peristomal 
infection was detected on clinical grounds using predefined clinical signs of infection 
at follow-up, by specially trained nurses who were unaware of the antibiotic 
prophylaxis given. This subjectiveness could introduce bias, but any such error ought 
to be evenly distributed due to the rather large sample size and the randomised double-
blinded design of the study. Moreover, the objective measures of infection (culture and 
blood tests) supported the findings. The patients included had to be able to give 
informed consent and perhaps this included a healthier group of patients compared to 
those who were unable to give consent. This could perhaps influence the 
generalisability of the study, but not its internal validity. Moreover, the infection 
frequency in both groups was comparable to the whole cohort of 484 patients (paper 
IV) as well as other PEG patients with antibiotic prophylaxis described in other 
trials.
168, 169
 
Advantages of the study are the randomised design, the blind administration of 
antibiotic prophylaxis to patients, follow-up by nurses without knowledge of given 
treatment, the objective markers of infection (bacterial cultures and blood chemistry), 
and the large sample size. 
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Paper IV 
This large cohort study comprised virtually all patients receiving PEG over the course 
of 4 years at one endoscopy centre, which included 484 patients with nearly complete 
follow-up.  The study was prospective and the potential risk factors and their 
categorisations were pre-determined, which should reduce the risk for bias. We wanted 
to analyse the two primary outcomes, 30-day mortality and peristomal infection at 
follow-up, in the best possible way. Since mortality was specified in time, but not the 
peristomal infections, we chose the Cox proportional hazard regression model 
regarding risk for short-term mortality and the logistic regression model regarding risk 
for peristomal infection. The trial gave access to a rich number of potential 
confounding variables, for which adjustments was made, thus limiting the risk of bias 
from confounding. There was a high proportion of missing data concerning tobacco 
smoking (25%) and BMI (31%), but they did not alter the risk estimates and were 
therefore excluded in the final analyses. Another issue regarding smoking is that many 
PEG patients had stroke and neurological disease, and were therefore unable to 
continue to smoke and many cancer patients may have stopped smoking after 
diagnosis of throat cancer where smoking is known to be a major risk factor. Because 
of such smoking cessation, the risk of post-operative infection due to the smoking 
effect might already have been reduced.
170, 171
 A test for biological interaction looking 
for departure from additivity was conducted between low albumin and high CRP, but 
was without statistical significance. 
The cut-off values for CRP and albumin were chosen before analyses and after 
studying the literature of comparable studies. Loss to follow-up (31 patients of whom 
20 died before follow-up) weakens the conclusions regarding risk of peristomal 
infections, especially since these patients were over-represented regarding low 
albumin and high CRP. 
Strengths of the study are the prospective design with a large number of participants, 
the complete follow-up with objective measures, and the abundance of data, allowing 
for adjustment for potential confounding.  
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Findings and implications 
Paper I 
This trial did not identify any obvious HRQL benefit from using ARS instead of CS. 
There were no statistically significant differences in HRQL score changes between 
baseline and 1 month between the ARS and the CS group, but the proportion of 
patients who completed the questionnaires at baseline and first follow-up at 1 month 
was reduced because of rapidly progressing disease and short survival. Some patients 
who were stented were not even able to fill in the baseline forms, which emphasises 
the importance of making the interval between randomisation and stent procedure as 
short as possible. This loss of patients contributed to a reduced statistical power. 
Nevertheless, this is hitherto the largest study addressing the issue of ARS in these 
patients. The decreasing inclusion rate indicates that larger studies on the subject could 
be very difficult to perform in the future, but the available trials may be useful in a 
meta-analysis.
172
 The ARS tested in this study was technically more difficult to insert 
and the procedure more time-consuming and, as the complication rate did not 
significantly differ between this and earlier studies, there is no significant reason to 
recommend the Esophageal Z-stent
®
 with a Dua Anti-reflux Valve instead of CS. The 
risk of reflux after stenting should, however, be stressed and any symptoms of reflux 
should be counteracted by a raised body position, especially immediately after a meal 
and medication could be tried for reduction of acid production even if the effect is 
uncertain in this category of patients.
39
 In case of future improvements in ARS design 
and delivery system, ARS could be considered but, if ARS are to be used in clinical 
practice, proof of their superiority over CS is essential.
26
  
 
 
Paper II 
This trial demonstrated no benefit from using losartan prophylactically during ERCP 
against post-procedural hyperenzymemia and pancreatitis. The hypothesis was based 
on experimental work among animals and the finding of a preventive effect of ARB on 
acute pancreatitis in general in a large case-control study.
135-141
 The reasons for a 
possibly true preventive effect not being shown could be due to limited sample size, 
inappropriate timing of the drug administration, low dose, the test drug perhaps not 
being the ARB with the best potency, or unknown confounding. So the question is 
whether or not we are missing a true effect (type 2 error)? There are some practical 
difficulties to solve if another trial is to be performed. For maximum effect, losartan 
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should be given 3-4 hours before ERCP, but since many patients arrive the same day 
as the investigation, this time limit would be difficult to achieve. Another difficulty is 
that more patients might need general anaesthesia during ERCP, because of the more 
advanced and time-consuming investigations done. The anaesthestists, in many cases, 
might not accept ARB taken the same day as general anaesthesia because of the risk of 
serious hypotension.
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 All this also applies to higher dosage and more potent ARBs. 
Therefore, it seems difficult to propose a larger randomised study using ARB as 
proposed prevention of post-ERCP pancreatitis. If the present study had shown a 
reduced risk of hyperenzymemia, we had planned a much larger study, using the same 
design, but evaluating a much larger sample size at several centres and addressing the 
risk of pancreatitis rather than hyperenzymemia alone. 
 
 
Paper III 
This clinical trial indicates that an oral solution of co-methoxazole administered in the 
PEG catheter after the PEG procedure is at least as good as standard antibiotic 
prophylaxis given intravenously before the PEG insertion. The literature has indicated 
that antibiotic prophylaxis is of value during the PEG procedure,
145
 but the present 
standard treatment with cefuroxime has many disadvantages, i.e. high costs, time-
consuming administration, the need to be given intravenously before the procedure 
which means unnecessary treatment whenever the PEG procedure fails, short 
biological effect, and ecological disadvantages.
151, 152
 These problems could all be 
solved by using the alternative sulphamethoxazole/trimethoprim, which also seems to 
have a local effect
174
 . Since this study provides scientifically robust evidence 
supporting the use of local sulphamethoxazole/trimethoprim and since it has several 
practical advantages, we can recommend this strategy in clinical practice. 
 
 
Paper IV 
The present cohort study regarding risk factors for short-term mortality within 30 days 
and peristomal infection at follow-up within 14 days indicates that low albumin and 
high CRP levels increase the risk of short term mortality more than 3-fold. Being older 
than 65 also involved an increased risk, while low BMI possibly could involve an 
added risk of mortality within 30 days. The corresponding parameters in relation to 
risk of peristomal infection within 14 days were weaker. The combination of low 
albumin and high CRP had a high relative risk for short-term mortality and this could 
perhaps be used as an indicator of patients that the PEG insertion should be postponed 
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until the patient is stronger. It is important to inform the patient, caring relatives or 
referring doctor about the high risk of early mortality. Low albumin and high CRP 
might be an indication of severe disease that in itself might lead to early mortality 
where the additional risk of a PEG might not be that important.  A patient with a very 
short life expectancy might therefore not benefit at all of a PEG which only might 
introduce pain and an added risk of complications. Instead it could be of value trying 
to optimise the patient e.g. antibiotics against infection, anti-inflammatory medication, 
and nutrition by other means of delivery. If the patient survives a couple of weeks and 
hopefully is less diseased, a new attempt at PEG may be contemplated.  
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Conclusions 
 The use of an anti-reflux stent in the palliation of inoperable distal oesophageal 
cancer might not be superior to conventional open stent from a HRQL 
perspective. 
 The angiotensin II receptor blocker losartan might not have any strong 
prenventive effect against hyperenzymemia after ERCP. 
 Injection of 20 ml sulphamethoxazole/trimethoprim solution into the newly 
inserted PEG catheter seems to be at least as good in preventing peristomal 
infection as standard treatment of 1.5 grams cefuroxime administered 
intravenously before the PEG. This new method could therefore be 
recommended as prophylaxis instead of standard treatment because of its 
positive clinical implications. 
 Low albumin combined with high CRP seems to predict a high risk of mortality 
within 30 days after PEG insertion. Such measures could be used to give the 
patient better information about the potential risks after PEG insertion and used 
in better decision-making regarding the timing of the PEG procedure. 
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Future perspective 
Endoscopic procedures will continue on the market for a long time and developments 
will probably bloom exponentially as new and better instruments are designed. Lateral 
thinking will help to find new ideas, new methods and new interventions. This will 
lead to the need for new, properly executed randomised trials in order to evaluate their 
suggested better effects. To assess unwanted side effects and risks, large cohort studies 
are needed. NOTES is the latest example of a new endoscopic field being investigated. 
Stenting of the gastrointestinal tract will require further improvement such as use of 
bio compatible materials with better design and properties. The antireflux stent for the 
distal oesophagus in palliative treatments of cancer may not be the stent of choice 
today but, with improved design and a more smoothly operated delivery system that 
might change. If other palliative treatments, such as new oncological therapies, 
prolong the survival of oesophageal cancer patients, the anti-reflux stent might be 
picked up again making new studies of their efficacy important. Comparing new stents 
with brachytherapy will then also be necessary.  
Combating post-ERCP pancreatitis is still a challenge, mainly because of its potential 
danger to the patient. The angiotensin II receptor blocker track might not be totally 
closed as yet. Newer agents of the same family with higher potency, longer biological 
half-life, faster absorption, and unique properties regarding oxidative stress and 
inflammatory response (e.g. telmisartan) might be useful. The chosen dose in our 
study might have been too low, as other studies suggest a higher dose could have 
better effect. The timing of drug intake is also of pharmacological importance for 
maximum effect. The hypotensive risk during general anaesthesia is probably not too 
difficult to resolve by perhaps using deep sedation (propofol) instead of general 
anaesthesia, better monitoring, proper counter measures, and interested anaesthetists. 
Better PEG catheter materials with effective antibacterial properties could perhaps be 
developed. The infection prophylactic introducer technique for PEG insertion will 
probably be developed to allow easier handling and to give better results regarding 
complications as compared to the pull PEG technique. Pre-PEG pharmacological 
treatments of chronic inflammation and acute infections in high-risk patients might 
have an impact on the survival after PEG but have to be properly tested. 
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Populärvetenskaplig sammanfattning på 
svenska 
 
Bakgrund: Endoskopi innebär att med hjälp av ett böjligt och styrbart optiskt 
instrument titta in i något av kroppens hålrum och när kirurgiska ingrepp görs med 
hjälp av endoskopi är det bland annat för att minska de risker som vanlig kirurgi för 
med sig. Under min tid som kirurg och endoskopist har jag mött patienter som tyvärr 
har drabbats av allvarliga biverkningar med svåra symtom efter endoskopiska ingrepp. 
Detta kan mer eller mindre helt förstöra den effekt ingreppet var tänkt att ha och även 
försämra patientens livskvalitet avsevärt och till och med leda till döden. Jag har därför 
blivit intresserad av att hitta metoder för att i möjligaste mån minska det lidande som 
endoskopiska biverkningar kan innebära. Det har gjort att jag engagerat mig i arbeten 
med syfte att testa vägar för att minska komplikationer och hitta faktorer som kan 
förutsäga en ökad risk för biverkningar vid ett antal specifika endoskopiska ingrepp i 
övre magtarmkanalen.  
De olika endoskopiska ingreppen för med sig biverkningar eller komplikationer som 
kan minskas med hjälp av ökad erfarenhet hos undersökaren, utveckling av bättre 
instrument och klokheten av att inte utföra ingreppen när risken för komplikationer 
verkar vara för stor. De här riskerna är trots allt mindre än när samma eller liknande 
ingrepp görs med hjälp av vanlig operation. För att göra de endoskopiska ingreppen 
ännu mindre riskfyllda måste man känna till det spektrum av biverkningar som kan ske 
vid de olika undersökningarna och de riskfaktorer som pekar mot ett sämre resultat.  
Det räcker inte med den enskilde undersökarens eller kirurgens erfarenheter utan 
kunskapen måste inhämtas från välplanerade och systematiskt utförda stora 
forskningsstudier. 
 
I den här avhandlingen ingår följande arbeten:  
Arbete 1: Behandling av patienter med obotbar matstrupscancer och sväljsvårigheter 
jämförande 2 olika typer av självexpanderande metallrör. 
Arbete 2: Ett försök att på medicinsk väg försöka minska risken för 
bukspottkörtelinflammation efter endoskopisk undersökning av gallgångar och 
bukspottkörtelgång. 
Arbete 3: Testning av en ny metod att ge antibiotika som infektionsskydd vid 
inläggning av en matningsslang direkt till magsäcken via bukväggen (inom vården ofta 
kallad PEG= perkutan endoskopisk gastrostomi). 
Arbete 4: Hitta faktorer som kan tala för ökad risk till tidig död och infektion efter 
PEG. 
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Arbete I: Matstrupscancer har uppvisat en kraftig ökning de senaste 30 åren men 
tyvärr kan större delen av patienterna inte botas eftersom sjukdomen upptäckts för sent 
eller på grund av att patienten är för svag för att tåla påfrestningen av en stor 
operation. Tyvärr drabbas nästa alla patienter med matstrupscancer av besvärande 
sväljsvårigheter och behöver därför ofta behandlas för det. Den vanligaste och 
snabbast verkande hjälpen till patienter som inte kan opereras är att med hjälp av ett 
självexpanderande metallrör på plats vidga förträngningen, vilket ofta har bra och 
snabb effekt på sväljningsbesvären. En annan sak att ta hänsyn till är att patienterna 
ofta inte överlever mer än några månader efter att diagnosen har ställts och därför 
behöver en hjälp fungerar snabbt och har bra effekt mot symtomen. En större del av 
matstrupstumörerna utvecklas nedtill i matstrupen vilket gör att de rör som placeras 
där, sträcker sig ned i magsäcken. Det här kan göra att magsäckens syra och övriga 
innehåll kan rinna upp i matstrupen (reflux) och ibland spilla över till luftrören. Det 
finns då risk för utveckling av svår inflammation i matstrupen och lungorna vilket kan 
ge besvärliga symtom som kan försämra patientens hälsoberoende livskvalitet 
avsevärt. Därför har metallrör med en envägs ventil (antirefluxventil) utvecklats som 
ska förhindra det här återflödet men flera studier har inte kunna påvisa någon säker 
förbättring jämfört de vanliga rören utan ventil. 
Den här studien testade om ett rör med antirefluxventil kunde förbättra den 
hälsoberoende livskvaliteten i förhållande till de patienter som fick ett standardrör utan 
ventil. Livskvalitet betyder olika saker för olika människor och kan omfatta väldigt 
många aspekter. Vi begränsade oss i den här studien till att mäta den påverkan som 
sjukdomen och behandlingen ger på patientens förmåga att leva sitt dagliga liv och på 
de symtom som patienten känner av på grund av sin sjukdom. Den här hälsoberoende 
livskvaliteten mättes med hjälp av frågeformulär, som analyserar symtom och dagliga 
funktioner både generellt vid cancer och specifikt vid mastrupscancer. Studien 
omfattar 65 patienter, vilket är fler än i tidigare studier men mindre än det antal som 
planerades. Patienterna i båda grupperna dog efter ca 2 månader (median) efter att 
röret lagts på plats, vilket var tidigare än förväntat. Vid analys av frågeformulären fann 
vi ingen statistisk skillnad mellan grupperna avseende livskvaliteten men konstigt nog 
sågs en poängmässig skillnad avseende symtom på reflux till det vanliga rörets fördel. 
Effekten mot sväljningssvårigheterna var likvärdig, men röret med ventil var tekniskt 
mer svårhanterat jämfört med standardröret. 
Således kunde vi inte med ledning av den här undersökningen se några säkra fördelar 
med det nya ventilförsedda röret jämfört med standardröret.  
 
Arbete II: Vid undersökning av gallgångarna och bukspottkörtelgången med ett 
endoskop (endoskopisk retrograd cholangiopankreatikografi=ERCP) för att t.ex. ta 
bort stenar eller lägga dit rör i gångarna för att avlasta förträngningar, finns risk för att 
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utlösa en inflammation i bukspottkörteln (pankreatit).  Vanligen är det inte en allvarlig 
åkomma men risken finns att det kan utvecklas till en mycket svår form med hög 
dödlighet. Bukspottkörtelinflammation konstateras genom att mäta speciella 
äggviteämnen i blodet (enzymer) efter ERCP och är dessa förhöjda mer än 3 gånger av 
det övre normalvärdet och patienten samtidigt känner smärta i magen kan man vara 
ganska övertygad om diagnosen. Enbart en höjning av enzymerna utan buksmärta efter 
ERCP är dock mycket vanligare. Eftersom de här enzymerna är förknippade med 
utveckling av bukspottkörtelinflammation ville vi i en första studie se om 
enzymstegringen påtagligt kunde dämpas av ett vanligt blodtryckssänkande läkemedel 
som losartan.  Idén hade vi fått från tidigare utförda undersökningar där man hade 
påvisat en skyddande effekt av losartan både mot enzymstegring och mot 
bukspottkörtelinflammation. 
I vår studie med slumpartad fördelning av losartan eller overksam substans (placebo) 
till patienter som gjorde ERCP så mätte vi enzymnivåerna efter undersökningen i upp 
till 24 timmar. Skulle vi se en hämmande effekt på enzymnivåerna hade vi tänkt oss en 
mycket större studie där vi ville se om det också finns en skyddande effekt mot 
bukspottkörtelinflammation efter ERCP. 
Analysen av studien visade att losartan, i den här studien, inte skyddar mot en stegring 
av enzymerna.  
 
Arbete III 
Patienter med svårigheter att svälja, ofta orsakat av stroke eller strål- och 
cellgiftbehandling av öron-näsa-halscancer, är ofta i behov av hjälp för att få i sig 
tillräckligt med näring. Att då lägga in en slang utifrån direkt in i magsäcken (PEG) 
med hjälp av endoskop kan vara till nytta för att kunna ge extra näring. Det är enkelt 
att göra men för med sig en hel del bekymmer oftast i form av infektioner längs 
kanalen genom bukväggen. Flera undersökningar har visat en bra effekt mot infektion 
när antibiotika används under ingreppet. Trots detta uppstår infektioner kring PEG 
slangen i upp till 10-15%. De är oftast lindriga men kan ändå ge problem med ökad 
smärta och förlängd vårdtid vilket leder till ökade kostnader. Ibland kan en utveckling 
ske till en mer allvarlig och riskfylld infektion med hög dödlighet. Ett vanligt använt 
antibiotikum är cefuroxim (Zinacef
®
) vilket har en hel del nackdelar. Det måste ges 
intravenöst innan operationen, vilket tyvärr kan glömmas bort och då leda till att PEG 
inläggningen kanske skjuts upp. Cefuroxim har dessutom kort verkningstid, hög 
kostnad och ges i onödan när PEG ingreppet misslyckas (5-10%). Det finns också en 
risk för en ogynnsam effekt på tarmens bakterier med risk för tjocktarmsinfektion 
orsakad av kraftig tillväxt av sjukdomsframkallande bakterier (clostridium difficile) 
vilket kan utlösas av bara en enda antibiotika dos. Ett alternativt antibiotikum skulle 
kunna vara sulfametoxazol/trimethoprim (Bactrim
®
) som ges i PEG katetern efter 
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ingreppet och skulle kunna lösa alla ovanstående nackdelar. Det här förutsätter då att 
det har minst lika bra effekt mot infektion som standardbehandlingen. Därför 
tilldelades något av dessa två antibiotika helt slumpartat i samband med PEG 
inläggning till de 234 patienter som deltog i studien.  
Vi kunde konstatera 10 infektioner hos patienterna som fick Bactrim
®
 och 14 
infektioner i Zinacef
®
 gruppen.  
En statistisk analys visade att Bactrim
®
 som ges på det här nya sättet är minst lika bra 
som Zinacef
®
 och därför på grund av sina övriga fördelar verkligen kan 
rekommenderas som infektionsskydd under PEG inläggningen. 
 
Arbete IV 
PEG är ett enkelt och snabbt genomfört ingrepp och man kan därför lätt luras att tro att 
det är ofarligt. Tyvärr kan patienterna drabbas av många olika komplikationer, 
vanligen infektion runt PEG slangen i 10-15% men patienterna, har det också visat sig, 
riskerar att avlida i en hög frekvens (8-28%) inom 30 dagar efter PEG inläggningen. 
Det rör ju sig ofta om patienter med svåra sjukdomar och då skulle kunskap om vilka 
riskfaktorer det finns för de här allvarliga komplikationerna vara av stort värde. Skulle 
man kunna förutse en stor risk hos en enskild patient, kanske man borde avråda 
patienten från att få PEG för tillfället eftersom det finns alternativa sätt att ge patienten 
näring. Under tiden kunde man kanske prova medicinsk behandling för att försöka få 
patienten i bättre form inför ett eventuellt nytt PEG-inläggningsförsök. 
Eftersom tidigare studier inte entydigt klarlagt riskfaktorer för dessa komplikationer, 
utförde vi en stor undersökning bland alla patienter som fick PEG mellan 2005 och 
2009 för att försöka hitta viktiga riskfaktorer för infektion eller tidig död efter PEG.  
De 484 som deltog följdes upp efter 2 veckor och dödsfall upp till 30 dagar efter PEG 
registrerades. Med ledning av tidigare undersökningar valde vi att titta på 6 
riskfaktorer: 1/ ≥65 års ålder, 2/ lågt albumin värde (<30 g/L), 3/ högt C-reaktivt 
protein (CRP) ≥10 mg/L), 4/ BMI < 18,5 kg/m2, 5/ orsaken för PEG behovet, samt 6/ 
ytterligare sjukdomar hos patienten. 
Statistisk analys visade att patienter med ålder ≥65 år, lågt albumin och högt CRP hade 
2-3 gånger ökad risk att dö inom 30 dagar efter PEG. Möjligen fanns även denna risk 
hos patienter med BMI <18,5. Hos patienter med både lågt albumin och högt CRP 
avled 20,5 %, inom 30 dagar, jämfört 2,6 % hos de patienter som hade normala 
värden. Lågt albumin ses ofta vid undernäring men förekommer också vid 
inflammatoriska tillstånd. CRP stegring ses vid akuta och kroniska inflammationer 
som kan orsakas av både bakterieinfektioner och andra svåra sjukdomar som t.ex. 
cancer. 
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Slutsatser: Hela det här avhandlingsarbetet har syftat till att försöka göra 
endoskopiska ingrepp mindre riskfyllda och ge mindre symtom och till att hitta 
riskfaktorer som skulle kunna ge patienten bättre information om vad som kan hända 
efter ingreppet och att det kanske kan göras vid en bättre tidpunkt:  
● Vi hittade inga säkra fördelar avseende hälsoberoende symtom och dagliga 
funktioner med att använda ett rör med inbyggd antirefluxventil, jämfört med 
standardröret utan ventil vid behandling av obotbar matstrupscancer.  
● Inte heller verkar risken för utveckling av ERCP-utlöst bukspottkörtelinflammation 
kunna minskas genom medicinsk förbehandling med det blodtryckssänkande 
läkemedlet losartan.  
● Däremot verkar en ny metod att ge antibiotika som skydd mot infektioner efter 
inlagd PEG vara minst lika bra jämfört standard behandling men har då istället stora 
fördelar genom att vara snabbare att ge, säkrare, billigare och leder inte till 
överbehandling om ingreppet misslyckas jämfört standardbehandlingen.  
● Patienter som får PEG och har låga albuminvärden kombinerat med höga CRP 
nivåer har stor risk att avlida inom 30 dagar efter ingreppet, vilket är viktig 
information att ge till patienten. Om en patient har dessa riskfaktorer så kan man 
kanske erbjuda en mindre riskfylld behandling genom att skjuta upp ingreppet och 
försöka behandla näringsbristen på annat sätt och samtidigt kanske dämpa 
inflammationen genom medicinsk behandling. Eventuellt kan patienten då hämta sig 
så att en PEG kan sättas dit vid ett senare tillfälle och då kanske med mindre risk, om 
då PEG behovet fortfarande finns kvar. 
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